Heart Failure Data

 

Sphingomab™ improves survival of mice after a myocardial infarction (heart attack)

In a well-established model of myocardial infarction ("MI"), whereby heart failure is the result, Sphingomab™-treated mice were approximately twice as likely to survive as the untreated mice.

[Actual data to be included at a subsequent date]